{"id":"NCT02006121","sponsor":"Britannia Pharmaceuticals Ltd.","briefTitle":"Clinical Trial of Apomorphine Subcutaneous Infusion in Patients With Advanced Parkinson's Disease","officialTitle":"Multicentre,Parallel-group,Double-blind,Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Apomorphine sc Infusion in Parkinson's Disease Patients With Motor Complications Not Well Controlled on Medical Treatment","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-03-03","primaryCompletion":"2016-06-06","completion":"2017-06-08","firstPosted":"2013-12-09","resultsPosted":"2019-07-08","lastUpdate":"2019-07-08"},"enrollment":107,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Parkinson's Disease"],"interventions":[{"type":"DRUG","name":"Apomorphine hydrochloride","otherNames":["Apo-go"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Apomorphine hydrochloride","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The primary objective of the trial was to investigate the efficacy of apomorphine continuous subcutaneous infusion compared to placebo in Parkinson's Disease patients with motor fluctuations not well controlled on medical treatment.\n\nThe secondary objective of the study was to investigate the safety and tolerability of apomorphine continuous subcutaneous therapy.","primaryOutcome":{"measure":"Mean Change in Daily OFF Time From Baseline (Start of Blinded Treatment) to the End of Double-blind Phase (Visit 10) Based on Patient Diaries Using MMRM mITT Population","timeFrame":"Baseline and 12 weeks","effectByArm":[{"arm":"Apomorphine Hydrochloride","deltaMin":-2.61,"sd":null},{"arm":"Placebo","deltaMin":-0.75,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0047"}]},"eligibility":{"minAge":"30 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":12,"exclusionCount":18},"locations":{"siteCount":20,"countries":["Austria","Denmark","France","Germany","Netherlands","Spain","United Kingdom"]},"refs":{"pmids":["33486139","30055903"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":23,"n":98},"commonTop":["Infusion site nodule","Nausea","Somnolence","Infusion site erythema","Dyskinesia"]}}